Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin
Abstract
In this concept paper the authors presents a unique and novel protocol to treat autoimmune diseases that may have the potential to reverse autoimmunity. It uses a combination of B cell depletion therapy (BDT), specifically rituximab (RTX) and intravenous immunoglobulin (IVIg), based on a specifically designed protocol (Ahmed Protocol). Twelve infusions of RTX are given in six or fourteen months. Once the CD20+ B cells are depleted from the...
Paper Details
Title
Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin
Published Date
Jul 18, 2018
Journal
Volume
9
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History